Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

myeloid leukaemia

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

Around one in three patients with early-stage breast cancer are considered high risk

- PMLiVE

MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe

The questionnaire gathered insights from 7,750 adults across five countries

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

MHRA urges companies to prepare for Windsor Framework for medicines

The new UK-wide arrangements for medicines will come into effect on 1 January 2025

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links